Investor & Media Home
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Learn more about our pipeline here.
Recent News
Nov 6, 2024
Oct 26, 2024
Oct 25, 2024
FRONT >> News > View All
View All Press Releases
Events & Presentations
Oct 28, 2024 at 8:00 AM EDT
Sep 25, 2024 at 12:00 PM EDT
Sep 20, 2024 at 10:00 AM EDT
FRONT > Events - View All
View All Events